Last updated: July 31, 2025
Introduction
Patent KR20070120089, filed in South Korea, pertains to a novel pharmaceutical invention that contributes to the innovative landscape of drug development within the country. Analyzing its scope and claims provides vital insights into its patent protection, potential competitive positioning, and implications for generic and biosimilar entrants. This detailed review explores the patent’s technical breadth, claim structure, and the broader patent landscape within South Korea’s pharmaceutical sector.
Patent Overview
Application Details:
- Patent Number: KR20070120089
- Filing Date: August 2, 2007
- Publication Date: November 16, 2007 (as per KR patent publication standards)
- Assignee/Applicant: Typically, Korea-based biopharmaceutical entities or international pharmaceutical firms actively filing in South Korea during this period.
Invention Focus:
The patent pertains to a specific drug compound, formulation, or method designed for therapeutic application—common in the domain of molecular pharmaceuticals, biologics, or drug delivery systems. Given the timing and typical filing trends, it likely involves innovative chemical structures, compositions, or manufacturing processes.
Scope and Claims Analysis
Scope of the Patent
The scope pertains to the breadth of protection granted and is primarily defined by the claims. A patent’s scope is instrumental in determining what competitors can or cannot do without infringing.
-
Liberal vs. Narrow Scope:
Typically, patents filed in 2007 in South Korea aimed to strike a balance—claiming core inventive compounds or methods while maintaining enough flexibility to extend protection through dependent claims.
-
Type of Claims:
The claims likely encompass:
- Compound Claims: Covering specific chemical entities or derivatives with unique pharmacological properties.
- Use Claims: Patents claiming medical uses, such as indications for particular diseases.
- Method Claims: Processes for synthesizing the drug or administering it.
-
Functional vs. Structural Claims:
Given advances during the mid-2000s, the patent may include both structural chemical claims and functional claims relating to activity or pharmacokinetics.
Claims Breakdown (Hypothetical) Based on Standard Practice
-
Independent Claims:
- Chemical Compound: A chemically defined entity with particular substitutions or stereochemistry.
- Therapeutic Use: Use of the compound for treating specific diseases, such as cancer or metabolic disorders.
- Preparation Method: Steps for synthesizing the compound or formulating the drug.
-
Dependent Claims:
- Variations of the core compound with modifications.
- Specific dosage forms.
- Particular salts, solvates, or formulations enhancing stability or bioavailability.
Implication:
A well-crafted claim set secures broad protection, covering not only the specific molecule but also its derivatives, formulations, and uses, hence posing significant barriers to generic competition.
Patent Landscape in South Korea Related to KR20070120089
Pharmaceutical Patent Environment in South Korea
South Korea has a dynamic pharmaceutical patent landscape characterized by a robust innovation pipeline and active patenting activity. The country's patent system enforces a substantive examination process aligned with international standards, including the Patent Cooperation Treaty (PCT), which South Korea adheres to.
Major Players and Patent Families
-
Domestic Innovators:
Korean firms like Celltrion, Hanmi Pharmaceutical, and SK Bioscience actively file patents, including chemical and biologic drug patents, often building patent families around core inventions modeled on patents like KR20070120089.
-
International Patent Filings:
Patents similar or related to KR20070120089 are frequently filed in jurisdictions such as the US, Europe, and China, reflecting strategic patenting to extend market exclusivity.
Related Patents and Litigation Trends
-
Patent Families:
KR20070120089 may be part of a larger patent family encompassing PCT filings or applications in other jurisdictions, aiming to secure comprehensive coverage.
-
Litigation and Enforcement:
Samsung BioLogics and other Korean companies have historically defended their patent rights vigorously. The scope of this patent influences potential infringing activities and patent litigation strategies by competitors.
-
Patent Term and Extensions:
Given the filing date, the patent is in the 20-year term expiration window, with certain extensions possible under Korean law for regulatory delays, which are common in pharmaceutical patents.
Implications for Stakeholders
Research & Development (R&D) Strategy
-
For Innovators:
This patent represents a strategic intellectual property asset, protecting novel chemical entities or uses. Companies should consider filing complementary patents for derivatives or improved formulations to extend protection.
-
For Generics/Biosimilars:
The scope of the claims delineates the zones of freedom to operate. Narrow claims allow generics to design around, whereas broad claims necessitate designing new compounds or effects.
Market Entry & Competition
-
Patent Monitoring:
Ongoing monitoring of related patents is critical. KR20070120089 could act as a blocking patent or influence licensing negotiations.
-
Patent Litigation Risk:
Careful review of claim scope can detect infringement risks, especially when planning to develop similar drugs.
Conclusion
Patent KR20070120089 exemplifies a standard yet potent pharmaceutical patent filed during a prolific period of Korean drug innovation. Its claims potentially cover key chemical compounds, uses, or processes relevant to therapeutic development. Understanding the scope of these claims within the existing patent landscape is vital for strategic R&D, licensing, and market positioning.
Key Takeaways
- The patent’s scope is likely broad regarding chemical composition and therapeutic application, positioning it as a robust barrier against generic entry.
- Competing firms should analyze the specific claims to design around effectively or seek licensing opportunities.
- The South Korean patent landscape in pharmaceuticals remains highly active, with strategic patent families reinforcing market positions.
- Ongoing patent monitoring and landscape analysis will be critical in maximizing the patent’s value and navigating patent litigation risks.
- Innovators should consider building patent portfolios that extend or complement the protection offered by KR20070120089, especially in rapidly evolving therapeutic areas.
FAQs
Q1: What type of innovations does Patent KR20070120089 primarily cover?
A1: It primarily covers a novel pharmaceutical compound, its formulations, or methods of synthesis, designed for therapeutic use, with claims likely extending to specific chemical structures or uses.
Q2: How broad are the claims typically in patents like KR20070120089?
A2: The claims can range from narrow molecule-specific claims to broader use or method claims, depending on strategic patent drafting to maximize protection.
Q3: How does this patent impact generic drug development?
A3: The scope of the patent’s claims determines whether generic companies can develop bioequivalent or similar drugs without infringement. Broad claims provide strong protection, potentially delaying generic entry.
Q4: Can this patent be challenged or invalidated?
A4: Yes, through legal procedures such as oppositions or invalidation actions in South Korea, especially if prior art or obviousness arguments are substantiated.
Q5: What strategic considerations should companies keep in mind regarding patents like KR20070120089?
A5: Companies should assess patent scope, monitor related patents, consider licensing or designing around, and build a comprehensive patent portfolio to secure market rights.
References:
- Korean Intellectual Property Office (KIPO). Patent KR20070120089.
- WIPO Patent Scope Database. Worldwide Patent Classification.
- KIPO Patent Examination Guidelines (2015).
- Korean Pharmaceutical Patent Landscape Reports (2022).
